# Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)

> **NCT04004793** · PHASE4 · COMPLETED · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 328 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **BEHAVIORAL:** Intensive lifestyle intervention
- **DRUG:** Dapagliflozin 10 MG Oral Tablet
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT04004793
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-12
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004793, "Remission of Type 2 Diabetes With Dapagliflozin (READ Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04004793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*